The Nasdaq Composite surged to a fresh all-time trading high on Friday as investors piled into equities, pushing the tech ...

Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a ...

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME.

Cornerstone Wealth Group LLC doubled down on Regeneron Pharmaceuticals, increasing its holdings by 114% in Q1. The fund now ...

ProPhase Labs Inc. (NASDAQ: PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced that ...

The Nasdaq 100 Index jumped to a record high this week, helped by the ongoing demand for artificial intelligence solutions ...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ...

Through this program, Regeneron has committed to matching donations at a one-to-one rate, up to a total of $200 million, for ...

Caesars Entertainment (NASDAQ:CZR) is one of the best S&P 500 stocks with huge upside potential. On June 24, Caesars Palace ...

LKQ Corporation (NASDAQ:LKQ) is one of the best S&P 500 stocks with huge upside potential. Towards the end of May, LKQ ...

Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.